Patents by Inventor Elizabeth Enlow
Elizabeth Enlow has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11713323Abstract: Described herein are certain crystalline forms of Compound 3, as well as pharmaceutical compositions employing the crystalline forms. Also provided are particles (e.g., nanoparticles) comprising such crystalline forms or pharmaceutical compositions. In certain examples, the particles are mucus penetrating particles (MPPs). The present invention further relates to methods of treating or preventing diseases using crystalline forms or pharmaceutical compositions.Type: GrantFiled: March 10, 2021Date of Patent: August 1, 2023Assignee: Kala Pharmaceuticals, Inc.Inventors: Elizabeth Enlow, Minh Ngoc Nguyen, Winston Z. Ong
-
Publication number: 20210355133Abstract: Described herein are certain crystalline forms of Compound 3, as well as pharmaceutical compositions employing the crystalline forms. Also provided are particles (e.g., nanoparticles) comprising such crystalline forms or pharmaceutical compositions. In certain examples, the particles are mucus penetrating particles (MPPs). The present invention further relates to methods of treating or preventing diseases using crystalline forms or pharmaceutical compositions.Type: ApplicationFiled: March 10, 2021Publication date: November 18, 2021Inventors: Elizabeth Enlow, Minh Ngoc Nguyen, Winston Z. Ong
-
Patent number: 10975090Abstract: Described herein are certain crystalline forms of Compound 3, as well as pharmaceutical compositions employing the crystalline forms. Also provided are particles (e.g., nanoparticles) comprising such crystalline forms or pharmaceutical compositions. In certain examples, the particles are mucus penetrating particles (MPPs). The present invention further relates to methods of treating or preventing diseases using crystalline forms or pharmaceutical compositions.Type: GrantFiled: March 2, 2020Date of Patent: April 13, 2021Assignee: Kala Pharmaceuticals, Inc.Inventors: Elizabeth Enlow, Minh Ngoc Nguyen, Winston Z. Ong
-
Publication number: 20210087192Abstract: Provided herein is a compound, 1-(4-(3-amino-[1,2,3]triazolo[1,5-a]pyridin-4-yl)phenyl)-3-(3-chlorophenyl)urea, pharmaceutical compositions thereof, and crystal forms thereof. Also provided are particles (e.g., nanoparticles) comprising the compound, and pharmaceutical compositions thereof, that are mucus penetrating. Also provided herein are methods and kits for using the compound, and pharmaceutical compositions thereof, for treating and/or preventing diseases associated with abnormal or pathological angiogenesis and/or aberrant signaling of a growth factor (e.g., vascular endothelial growth factor (VEGF)), such as proliferative diseases (e.g., cancers, benign neoplasms, inflammatory diseases, autoimmune diseases) and ocular diseases (e.g., macular degeneration, glaucoma, diabetic retinopathy, retinoblastoma, edema, uveitis, dry eye, blepharitis, and post-surgical inflammation) in a subject in need thereof.Type: ApplicationFiled: December 4, 2020Publication date: March 25, 2021Inventors: Pawel Wojciech Nowak, Minh Ngoc Nguyen, Elizabeth Enlow, Winston Zapanta Ong
-
Patent number: 10875857Abstract: Provided herein is a compound, 1-(4-(3-amino-[1,2,3]triazolo[1,5-a]pyridin-4-yl)phenyl)-3-(3-chlorophenyl)urea, pharmaceutical compositions thereof, and crystal forms thereof. Also provided are particles (e.g., nanoparticles) comprising the compound, and pharmaceutical compositions thereof, that are mucus penetrating. Also provided herein are methods and kits for using the compound, and pharmaceutical compositions thereof, for treating and/or preventing diseases associated with abnormal or pathological angiogenesis and/or aberrant signaling of a growth factor (e.g., vascular endothelial growth factor (VEGF)), such as proliferative diseases (e.g., cancers, benign neoplasms, inflammatory diseases, autoimmune diseases) and ocular diseases (e.g., macular degeneration, glaucoma, diabetic retinopathy, retinoblastoma, edema, uveitis, dry eye, blepharitis, and post-surgical inflammation) in a subject in need thereof.Type: GrantFiled: November 29, 2018Date of Patent: December 29, 2020Assignee: Kala Pharmaceuticals, Inc.Inventors: Pawel Wojciech Nowak, Minh Ngoc Nguyen, Elizabeth Enlow, Winston Zapanta Ong
-
Publication number: 20200216459Abstract: Described herein are certain crystalline forms of Compound 3, as well as pharmaceutical compositions employing the crystalline forms. Also provided are particles (e.g., nanoparticles) comprising such crystalline forms or pharmaceutical compositions. In certain examples, the particles are mucus penetrating particles (MPPs). The present invention further relates to methods of treating or preventing diseases using crystalline forms or pharmaceutical compositions.Type: ApplicationFiled: March 2, 2020Publication date: July 9, 2020Inventors: Elizabeth Enlow, Minh Ngoc Nguyen, Winston Z. Ong
-
Patent number: 10618906Abstract: Described herein are certain crystalline forms of Compound 3, as well as pharmaceutical compositions employing the crystalline forms. Also provided are particles (e.g., nanoparticles) comprising such crystalline forms or pharmaceutical compositions. In certain examples, the particles are mucus penetrating particles (MPPs). The present invention further relates to methods of treating or preventing diseases using crystalline forms or pharmaceutical compositions.Type: GrantFiled: November 8, 2018Date of Patent: April 14, 2020Assignee: Kala Pharmaceuticals, Inc.Inventors: Elizabeth Enlow, Minh Ngoc Nguyen, Winston Z. Ong
-
Patent number: 10253045Abstract: Disclosed herein are certain crystalline forms of Compound 5, N-(5-((2-(4-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butanamido)imidazo[1,2-0]pyridazin-6-yl)oxy)-2-methylphenyl)-1,3-dimethyl-1/-/-pyrazole-5-carboxamide, as well as pharmaceutical compositions comprising the crystalline forms. The present disclosure further relates to methods for treating or preventing diseases or disorders using the crystalline forms or pharmaceutical compositions thereof in a subject in need thereof, including diseases or disorders associated with abnormal or pathological angiogenesis and/or aberrant signaling of a growth factor signaling pathway (e.g., vascular endothelial growth factor (VEGF)), such as proliferative diseases and ocular diseases.Type: GrantFiled: November 24, 2015Date of Patent: April 9, 2019Assignee: Kala Pharmaceuticals, Inc.Inventors: Tadeas Liska, Elizabeth Enlow, Jinsoo Kim, Winston Ong
-
Publication number: 20190092772Abstract: Provided herein is a compound, 1-(4-(3-amino-[1,2,3]triazolo[1,5-a]pyridin-4-yl)phenyl)-3-(3-chlorophenyl)urea, pharmaceutical compositions thereof, and crystal forms thereof. Also provided are particles (e.g., nanoparticles) comprising the compound, and pharmaceutical compositions thereof, that are mucus penetrating. Also provided herein are methods and kits for using the compound, and pharmaceutical compositions thereof, for treating and/or preventing diseases associated with abnormal or pathological angiogenesis and/or aberrant signaling of a growth factor (e.g., vascular endothelial growth factor (VEGF)), such as proliferative diseases (e.g., cancers, benign neoplasms, inflammatory diseases, autoimmune diseases) and ocular diseases (e.g., macular degeneration, glaucoma, diabetic retinopathy, retinoblastoma, edema, uveitis, dry eye, blepharitis, and post-surgical inflammation) in a subject in need thereof.Type: ApplicationFiled: November 29, 2018Publication date: March 28, 2019Inventors: Pawel Wojciech Nowak, Minh Ngoc Nguyen, Elizabeth Enlow, Winston Zapanta Ong
-
Publication number: 20190077810Abstract: Described herein are certain crystalline forms of Compound 3, as well as pharmaceutical compositions employing the crystalline forms. Also provided are particles (e.g., nanoparticles) comprising such crystalline forms or pharmaceutical compositions. In certain examples, the particles are mucus penetrating particles (MPPs). The present invention further relates to methods of treating or preventing diseases using crystalline forms or pharmaceutical compositions.Type: ApplicationFiled: November 8, 2018Publication date: March 14, 2019Inventors: Elizabeth Enlow, Minh Ngoc Nguyen, Winston Z. Ong
-
Patent number: 10174022Abstract: Provided herein is a compound, 1-(4-(3-amino-[1,2,3]triazolo[1,5-a]pyridin-4-yl)phenyl)-3-(3-chlorophenyl)urea, pharmaceutical compositions thereof, and crystal forms thereof. Also provided are particles (e.g., nanoparticles) comprising the compound, and pharmaceutical compositions thereof, that are mucus penetrating. Also provided herein are methods and kits for using the compound, and pharmaceutical compositions thereof, for treating and/or preventing diseases associated with abnormal or pathological angiogenesis and/or aberrant signaling of a growth factor (e.g., vascular endothelial growth factor (VEGF)), such as proliferative diseases (e.g., cancers, benign neoplasms, inflammatory diseases, autoimmune diseases) and ocular diseases (e.g., macular degeneration, glaucoma, diabetic retinopathy, retinoblastoma, edema, uveitis, dry eye, blepharitis, and post-surgical inflammation) in a subject in need thereof.Type: GrantFiled: December 10, 2015Date of Patent: January 8, 2019Assignee: Kala Pharmaceuticals, Inc.Inventors: Pawel Wojciech Nowak, Minh Ngoc Nguyen, Elizabeth Enlow, Winston Zapanta Ong
-
Patent number: 10160765Abstract: Described herein are certain crystalline forms of Compound 3, as well as pharmaceutical compositions employing the crystalline forms. Also provided are particles (e.g., nanoparticles) comprising such crystalline forms or pharmaceutical compositions. In certain examples, the particles are mucus penetrating particles (MPPs). The present invention further relates to methods of treating or preventing diseases using crystalline forms or pharmaceutical compositions.Type: GrantFiled: September 22, 2017Date of Patent: December 25, 2018Assignee: Kala Pharmaceuticals, Inc.Inventors: Elizabeth Enlow, Minh Ngoc Nguyen, Winston Z. Ong
-
Publication number: 20180057489Abstract: Provided herein is a compound, 1-(4-(3-amino-[1,2,3]triazolo[1,5-a]pyridin-4-yl)phenyl)-3-(3-chlorophenyl)urea, pharmaceutical compositions thereof and crystal forms thereof. Also provided are particles (e.g., nanoparticles) comprising the compound, and pharmaceutical compositions thereof that are mucus penetrating. Also provided herein are methods and kits for using the compound, and pharmaceutical compositions thereof for treating and/or preventing diseases associated with abnormal or pathological angiogenesis and/or aberrant signaling of a growth factor (e.g., vascular endothelial growth factor (VEGF)), such as proliferative diseases (e.g., cancers, benign neoplasms, inflammatory diseases, autoimmune diseases) and ocular diseases (e.g., macular degeneration, glaucoma, diabetic retinopathy, retinoblastoma, edema, uveitis, dry eye, blepharitis, and post-surgical inflammation) in a subject in need thereof.Type: ApplicationFiled: December 10, 2015Publication date: March 1, 2018Inventors: Pawel Wojciech Nowak, Minh Ngoc Nguyen, Elizabeth Enlow, Winston Zapanta Ong
-
Patent number: 9890173Abstract: Described herein is certain crystalline forms of Compound 5, as well as pharmaceutical compositions employing the crystalline forms. Also provided are particles (e.g., nanoparticles) comprising such crystalline forms or pharmaceutical compositions. In certain examples, the particles are mucus penetrating particles (MPPs). The present invention further relates to methods of treating or preventing diseases using crystalline forms or pharmaceutical compositions.Type: GrantFiled: May 24, 2017Date of Patent: February 13, 2018Assignee: Kala Pharmaceuticals, Inc.Inventors: Elizabeth Enlow, Minh Ngoc Nguyen, Winston Z. Ong
-
Publication number: 20180009824Abstract: Described herein are certain crystalline forms of Compound 3, as well as pharmaceutical compositions employing the crystalline forms. Also provided are particles (e.g., nanoparticles) comprising such crystalline forms or pharmaceutical compositions. In certain examples, the particles are mucus penetrating particles (MPPs). The present invention further relates to methods of treating or preventing diseases using crystalline forms or pharmaceutical compositions.Type: ApplicationFiled: September 22, 2017Publication date: January 11, 2018Inventors: Elizabeth Enlow, Minh Ngoc Nguyen, Winston Z. Ong
-
Publication number: 20170313724Abstract: Disclosed herein are certain crystalline forms of Compound 5, N-(5-((2-(4-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butanamido)imidazo[1,2-0]pyridazin-6-yl)oxy)-2-methylphenyl)-1,3-dimethyl-1/-/-pyrazole-5-carboxamide, as well as pharmaceutical compositions comprising the crystalline forms. The present disclosure further relates to methods for treating or preventing diseases or disorders using the crystalline forms or pharmaceutical compositions thereof in a subject in need thereof, including diseases or disorders associated with abnormal or pathological angiogenesis and/or aberrant signaling of a growth factor signaling pathway (e.g., vascular endothelial growth factor (VEGF)), such as proliferative diseases and ocular diseases.Type: ApplicationFiled: November 24, 2015Publication date: November 2, 2017Inventors: Tadeas Liska, Elizabeth Enlow, Jinsoo Kim, Winston Ong
-
Patent number: 9790232Abstract: Described herein are certain crystalline forms of Compound 3, as well as pharmaceutical compositions employing the crystalline forms. Also provided are particles (e.g., nanoparticles) comprising such crystalline forms or pharmaceutical compositions. In certain examples, the particles are mucus penetrating particles (MPPs). The present invention further relates to methods of treating or preventing diseases using crystalline forms or pharmaceutical compositions.Type: GrantFiled: December 28, 2015Date of Patent: October 17, 2017Assignee: Kala Pharmaceuticals, Inc.Inventors: Elizabeth Enlow, Minh Ngoc Nguyen, Winston Zapanta Ong
-
Publication number: 20170260193Abstract: Described herein is certain crystalline forms of Compound 5, as well as pharmaceutical compositions employing the crystalline forms. Also provided are particles (e.g., nanoparticles) comprising such crystalline forms or pharmaceutical compositions. In certain examples, the particles are mucus penetrating particles (MPPs). The present invention further relates to methods of treating or preventing diseases using crystalline forms or pharmaceutical compositions.Type: ApplicationFiled: May 24, 2017Publication date: September 14, 2017Inventors: Elizabeth Enlow, Minh Ngoc Nguyen, Winston Z. Ong
-
Patent number: 9688688Abstract: Described herein are certain crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one, as well as pharmaceutical compositions employing the crystalline forms. Also provided are particles (e.g., nanoparticles) comprising such crystalline forms or pharmaceutical compositions. In certain examples, the particles are mucus penetrating particles (MPPs). Also described are methods of treating and/or preventing diseases using the crystalline forms or pharmaceutical compositions described herein.Type: GrantFiled: November 3, 2014Date of Patent: June 27, 2017Assignee: Kala Pharmaceuticals, Inc.Inventors: Elizabeth Enlow, Minh Ngoc Nguyen, Winston Z. Ong
-
Patent number: 9458169Abstract: Described herein is certain crystalline forms of Compound 3, as well as pharmaceutical compositions employing the crystalline forms. Also provided are particles (e.g., nanoparticles) comprising such crystalline forms or pharmaceutical compositions. In certain examples, the particles are mucus penetrating particles (MPPs). The present invention further relates to methods of treating or preventing diseases using crystalline forms or pharmaceutical compositions.Type: GrantFiled: October 31, 2014Date of Patent: October 4, 2016Assignee: Kala Pharmaceuticals, Inc.Inventors: Elizabeth Enlow, Minh Ngoc Nguyen, Winston Ong